MARLBOROUGH, Mass., Oct. 14, 2019 /PRNewswire/ --
WHO: | Hologic, Inc. HOLX, is the maker of the Genius™ 3D Mammography™ exam, the only mammogram clinically proven to detect 20 to 65 percent more invasive breast cancers compared to 2D mammography alone.1,2 |
WHAT: | October is Breast Cancer Awareness Month and Grammy award-winning artist and breast cancer survivor Sheryl Crow is encouraging women to make breast cancer screening a priority. Sheryl is joined by Dr. Jessica Shepherd, a leading OB/GYN and women's health expert, to discuss the importance of breast cancer screenings and what women need to know about a more comfortable and more accurate experience during their mammograms. |
For years, women have reported avoiding regular mammograms due in large part to the fear of discomfort associated with breast compression. In fact, a recent survey found that fear of physical discomfort was the top reason cited for avoiding a mammogram by women who never had one. | |
Fortunately, Hologic now offers the SmartCurve™ breast stabilization system, which features a proprietary curved surface that mirrors the shape of a woman's breast to reduce pinching and allow better distribution of force over the entire breast. The system also features proprietary image processing algorithms that ensure the preservation of image quality and accuracy. | |
In a clinical study comparing the SmartCurve system to standard compression, the SmartCurve system improved comfort in 93 percent of women who reported moderate to severe discomfort with standard compression. In addition, 95 percent of those surveyed would recommend facilities that use the system.3 |
The Genius™ 3D Mammography™ exam (also known as the Genius™ exam) is only available on a Hologic® 3D Mammography™ system. The Genius™ exam consists of a 2D and 3D™ image set, where the 2D image can be either an acquired 2D image or a 2D image generated from the 3D™ image set. There are more than 6,000 Hologic 3D Mammography™ systems in use across the United States, so women have convenient access to the Genius™ exam. To learn more about the Genius™ exam, visit http://www.Genius3DNearMe.com.
Media Contact
Jane Mazur
508.263.8764 (direct)
585.355.5978 (mobile)
jane.mazur@hologic.com
1 Results from Friedewald, SM, et al. "Breast cancer screening using tomosynthesis in combination with digital mammography." JAMA 311.24 (2014): 2499-2507; a multi-site (13), non-randomized, historical control study of 454,000 screening mammograms investigating the initial impact the introduction of the Hologic Selenia® Dimensions® on screening outcomes. Individual results may vary. The study found an average 41% increase and that 1.2 (95% CI: 0.8-1.6) additional invasive breast cancers per 1,000 screening exams were found in women receiving combined 2D FFDM and 3D™ mammograms acquired with the Hologic 3D Mammography™ System versus women receiving 2D FFDM mammograms only.
2 Bernardi D, Macaskill P, Pellegrini M, et. al. Breast cancer screening with tomosynthesis (3D mammography) with acquired or synthetic 2D mammography compared with 2D mammography alone (STORM-2): a population-based prospective study. Lancet Oncol. 2016 Aug;17(8):1105-13.
3 Smith, A. Improving Patient Comfort in Mammography. Hologic WP-00019 Rev 003 (2017).
SOURCE Hologic, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
